Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Immunic Inc chart...

About the Company

immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu

CEO

Daniel Vitt

Exchange

NASDAQ

$M

Total Revenue

58

Employees

$59M

Market Capitalization

-0.46

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $IMUX News

Immunic And 2 Other Stocks Under $2 Insiders Are Buying

on MSN ago, source:

The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their ...

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

25d ago, source: Yahoo Finance

2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune ...

Immunic (NASDAQ: IMUX)

3d ago, source: The Motley Fool

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

18d ago, source: Nasdaq

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic ...

Immunic reports successful 2023 and prepares for key 2025 milestones

25d ago, source: Nasdaq

Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023. Clinically, Immunic achieved positive results across its portfolio, including ...

Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month

23h ago, source: Proactiveinvestors

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return ...

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024

19d ago, source: Stockhouse

NEW YORK, Feb. 29, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory ...

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

25d ago, source: Yahoo Finance

About Immunic, Inc. Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune ...

Immunic reports successful 2023 and prepares for key 2025 milestones

26d ago, source: Yahoo Finance

Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion following what he described as a successful 2023. Outlining the company's achievements, Dr Vitt noted the company strengthened its ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...